Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) pipeline Target constitutes close to 53 molecules. Out of which approximately 53 molecules are developed by companies. The latest report Tyrosine Protein Kinase JAK1 - Drugs In Development, 2022, outlays comprehensive information on the Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - JAK1 is a human tyrosine kinase protein essential for signaling for certain type I and type II cytokines. JAK1 plays a critical role in initiating responses to multiple major cytokine receptor families. Expression of JAK1 in cancer cells enables individual cells to contract, potentially allowing them to escape their tumor and metastasize to other parts of the body. The molecules developed by companies in Archived (Marketed), Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 5, 7, 10, 10, 17, 1 and 1 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively.

Report covers products from therapy areas Immunology, Dermatology, Gastrointestinal, Oncology, Musculoskeletal Disorders, Infectious Disease, Respiratory, Central Nervous System, Cardiovascular, Hematological Disorders, Metabolic Disorders, Genetic Disorders, Genito Urinary System And Sex Hormones, Ophthalmology and Women's Health which include indications Rheumatoid Arthritis, Atopic Dermatitis (Atopic Eczema), Alopecia Areata, Ulcerative Colitis, Psoriasis, Inflammatory Bowel Disease, Graft Versus Host Disease (GVHD), Systemic Lupus Erythematosus, Vitiligo, Ankylosing Spondylitis (Bekhterev's Disease), Coronavirus Disease 2019 (COVID-19), Crohn's Disease (Regional Enteritis), Inflammation, Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Autoimmune Disorders, Dermatitis (Eczema), Diffuse Large B-Cell Lymphoma, Multiple Sclerosis, Peripheral T-Cell Lymphomas (PTCL), Sicca Syndrome (Sjogren), Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Anaplastic Large Cell Lymphoma (ALCL), Asthma, B-Cell Non-Hodgkin Lymphoma, Bronchiolitis Obliterans, Chronic Lymphocytic Leukemia (CLL), Coronavirus Disease 2019 (COVID-19) Associated Cytokine Release Syndrome, Cutaneous T-Cell Lymphoma, Giant Cell Arteritis (Temporal Arteritis/Cranial Arteritis/Horton Disease), Head And Neck Cancer Squamous Cell Carcinoma, Hemophagocytic Lymphohistiocytosis, Hidradenitis Suppurativa, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Mantle Cell Lymphoma, Myelodysplastic Syndrome, Non-Small Cell Lung Cancer, Plaque Psoriasis (Psoriasis Vulgaris), Prurigo, Psoriatic Arthritis, Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease), T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia), Triple-Negative Breast Cancer (TNBC), Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma), Aicardi-Goutieres Syndrome (AGS), Allergies, Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Arthritis, Auto Inflammatory Disease, Axial Spondyloarthritis, B-Cell Chronic Lymphocytic Leukemia, Breast Hyperplasia, Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE), Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis), Chronic Kidney Disease (Chronic Renal Failure), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Chronic Myelomonocytic Leukemia (CMML), Chronic Obstructive Pulmonary Disease (COPD), Colon Cancer, Colorectal Cancer, Cutaneous Lupus Erythematosus, Cytokine Release Syndrome (Cytokine Storm), Diabetic Macular Edema, Endometrial Cancer, Eosinophilic Esophagitis, Epstein-Barr Virus (HHV-4) Infections, Essential Thrombocythemia, Focal Segmental Glomerulosclerosis (FSGS), Follicular Lymphoma, Gastric Cancer, Granulomatosis with Polyangiitis (Wegener's Granulomatosis), Hairy Cell Leukemia, Hand Dermatitis, Hematopoietic Stem Cell Transplantation, Hepatocellular Carcinoma, Hypereosinophilic Syndrome, Hypopharyngeal Cancer, Idiopathic Pulmonary Fibrosis, Juvenile Arthritis, Keratoconjunctivitis Sicca (Dry Eye), Kidney Cancer (Renal Cell Cancer), Laryngeal Cancer, Leiomyosarcoma, Lipodystrophy (Lipoatrophy), Lupus Erythematosus, Lupus Nephritis, Lymphoma, Marginal Zone B-cell Lymphoma, Melanoma, Mild Cognitive Impairment, Myeloproliferative Disorders, Myxoid Liposarcoma, Natural Killer Cell Lymphomas, Non-Hodgkin Lymphoma, Oligoarticular Idiopathic Juvenile Arthritis, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Osteoarthritis, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Polyarticular Juvenile Idiopathic Arthritis (PJIA), Polycythemia Vera, Polymyalgia Rheumatica (PMR), Pruritus, Pulmonary Arterial Hypertension, Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Renal Cell Carcinoma, Secondary Myelofibrosis, Sezary Syndrome, Skin Cancer, Solid Tumor, Spondyloarthritis (Spondyloarthropathy), Squamous Cell Carcinoma, Synovial Sarcoma, Systemic Idiopathic Juvenile Arthritis, T-Cell Lymphomas, Takayasu Arteritis, Thrombocythemia Myelofibrosis and Transitional Cell Carcinoma (Urothelial Cell Carcinoma).

Furthermore, this report also reviews key players involved in Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

• The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2)
• The report reviews Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
• The report assesses Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2)) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2)
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies Mentioned
Companies Mentioned

AbbVie Inc
Aclaris Therapeutics Inc
Alexion Pharmaceuticals Inc
Aqilion AB
Ashvattha Therapeutics LLC
Astellas Pharma Inc
Bristol-Myers Squibb Co
Celon Pharma SA
Concert Pharmaceuticals Inc
Dizal (Jiangsu) Pharmaceutical Co Ltd
Eli Lilly and Co
EQRx Inc
Galapagos NV
GlaxoSmithKline Plc
Han Wha Pharma Co Ltd
Hangzhou East China Pharmaceutical Group Co Ltd
HK inno.N Corp
Impetis Biosciences Ltd
Incyte Corp
Japan Tobacco Inc
Jiangsu Carephar Pharmaceutical Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Jiangsu Vcare PharmaTech Co Ltd
Kinaset Therapeutics Inc
Lynk Pharmaceutical Hangzhou Co Ltd
Merck & Co Inc
Nippon Shinyaku Co Ltd
Pfizer Inc
Sareum Holdings Plc
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Shenzhen Chipscreen Biosciences Co Ltd
Sichuan Kelun Bio-Tech Pharmaceutical Co Ltd
Sierra Oncology Inc
Simcere Pharmaceutical Group Ltd
The United Laboratories International Holdings Ltd
Theravance Biopharma Inc
TLL Pharmaceutical LLC
Wuxi Fuxin Pharmaceutical Research and Development Co Ltd